Know Labs Awarded Foundational Patent for Bio-RFID Tech

Know Labs Inc., an emerging leader in non-invasive medical diagnostics, has been granted another foundational patent for its Bio-RFIDTM technology. This new patent brings Know Labs portfolio to 23 issued and 34 pending patents, enhances the company’s technological leadership position and brings Know Labs one step closer to U.S. Food and Drug Administration (FDA) submission and commercial launch.
 
“Our technology platform has the potential to disrupt the medical diagnostic industry because of its unique ability to detect and measure analytes such as glucose using radio frequency spectroscopy. Our innovative approach and the technology behind it have tremendous long-term value, which we are protecting through a disciplined intellectual property strategy,” said Ron Erickson, Know Labs founder and chairman. “We expect to receive other critical patents soon, which, combined with our current portfolio, support our path to commercial launch.”
 
U.S. Patent No. 11,058,331 was issued by the U.S. Patent and Trademark Office and is titled “Analyte Sensor and System with Multiple Detector Elements that can Transmit or Receive.” The patent relates to the technology that allows the implementation of radio frequency scans using different combinations of antennas to improve the detection capabilities of the Bio-RFID sensors in non-invasively measuring and identifying analytes, including glucose.
 
“This patent covers how the antennas used by the Bio-RFID technology platform could be arranged, which will be critical for building a variety of medical devices focused on other analytes,” said Phil Bosua, Bio-RFID inventor and Know Labs CEO. “Our current focus is on launching what we believe will be the world’s first non-invasive glucose monitoring device. This foundational patent protects the broad application of Bio-RFID and is another important milestone toward a revolution in medical diagnostic technology.”
 
Know Labs is a public company whose shares trade under the stock symbol “KNWN.” The company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The company refers to its technology as Bio-RFID. The Bio-RFID technology can be integrated into a variety of wearable, mobile, or bench-top form factors. This patented and patent-pending technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of its Bio-RFID technology will be in a product marketed as a glucose monitor. It will provide the user with real-time information on their blood glucose levels. This product will require FDA approval prior to its introduction to the market.